Clinical trial
BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By…
NCT00297063 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00297063 |
|---|---|
| Title | BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy- |
| Official title | Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus (Monotherapy) - Double-Blind Comparative Study of Rosiglitazone Maleate vs. Pioglitazone Hydrochloride and Placebo - |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Rosiglitazone |
| Enrollment | 350 |
| Start date | Jan 11, 2006 |
| Primary completion | May 31, 2007 |
| Completion | May 31, 2007 |
| First posted | Feb 27, 2006 |
| Last update posted | Nov 18, 2022 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: